Current Clinical Studies

Artificial Intelligence: CURATE.AI

CURATE.AI: MCRPC

N.1 Labs is currently conducting a prospective, first-in-human interventional study pertaining to CURATE.AI-driven optimisation of solid tumor combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients.

UPDATE: N.1 Labs team publishes Cover Article demonstrating durable response and halted disease progression in patient with metastatic castration resistant prostate cancer. More information can be found here.

CURATE.AI: GC

N.1 Labs has received approval to conduct a prospective expanded access interventional study pertaining to CURATE.AI-driven optimisation of gastric cancer combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients (In collaboration with Tan Tock Seng Hospital).

CURATE.AI: HCC

CURATE.AI: LT

N:1 Labs is currently conducting a prospective interventional study pertaining to CURATE.AI-driven optimisation of post-transplant immunosuppression. This is a N-of-1 clinical trial and patient recruitment is pending (Clinicaltrials.gov: NCT03527238)

Results from the first-in-human study can be found in Science Translational Medicine, 333ra49, 2016 http://stm.sciencemag.org/content/8/333/333ra49

Nanomedicine

NDGP (Nano 1)

We have received approval to initiate clinical studies to validate Nanodiamond-Gutta Percha (NDGP) as a non-surgical root canal biomaterial (Clinicaltrials.gov: NCT02698163).

Results from the first-in-human study can be found in PNAS, E9445, 2017 http://www.pnas.org/content/114/45/E9445

GPx (Nano 2)

We have received approval to initiate clinical studies to validate a therapeutic-Nanodiamond-GP (GPx) device (Clinicaltrials.gov: NCT03376984).